Clinical Medication Analysis of Clopidogrel and Aspirin Guided by Medicine Gene Detection

Objective: Medicine gene detection is used to guide the clinical use of clopidogrel and aspirin, in order to improve the efficacy and safety of clinical treatment. Methods: A total of 214 patients who received clopidogrel and aspirin treatment at the Affiliated Nanhua Hospital of the University of South China from March 2022 to February 2023 were selected. The medicine genes were detected by pyrosequencing. The genotype distribution of each gene locus was tested by the Hardy-Weinberg equilibrium test with SPSS 26.0. The patients' clinical information was analyzed using the chi-square test and binary logistic regression. Results: Among the 130 patients using clopidogrel, gene loci CYP2C19*2 681 G>A and CYP2C19*3 636 G>A were detected. Among the 84 patients using aspirin, gene loci PEAR1 G>A and LTC4S A>C were detected. The gene frequency distribution of the gene loci all accorded with Hardy-Weinberg equilibrium law, which indicated the sample was group representation. 59.2% of patients had clopidogrel resistance, 72.6% of patients had aspirin resistance, and 33.3% of patients had a high risk of urticaria when using aspirin. However, there was no significant difference in clopidogrel and aspirin resistance or urticaria risk in relation to patients' clinical information (P > 0.05). The results of medicine gene detection could be used as an independent indicator to predict the efficacy and safety of using clopidogrel and aspirin, providing important guidance for the clinical use of medication. Conclusion: Medicine gene detection could promote individualized medication and improve the efficacy and safety of clinical treatment when guiding the use of clopidogrel and aspirin.